This article explains, in educational terms, vascular closure device — how the technology works and where it fits. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open.
Arterial Access Closure
After the sheath is removed, the arterial access site must be closed, either with manual compression or with a vascular closure device. Closure devices are designed to seal the arteriotomy and can shorten time to hemostasis and ambulation in appropriately selected patients. INVAMED's AngioTEN Vascular Closure System is positioned for this access-site management role. Whether a closure device is used, and which type, is determined by access site, sheath size, and clinician preference.
Design and Technical Notes
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU. Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Key Considerations
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
- Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting.
- Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Frequently Asked Questions
What is the INVAMED drug-eluting stent called?
INVAMED's drug-eluting coronary stent is the ATLAS Drug Eluting Coronary Stent System, built on a cobalt-chromium L605 platform with a sirolimus coating.
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
Does INVAMED make a drug-coated coronary balloon?
Yes. The Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for local drug delivery, such as in-stent restenosis or small-vessel disease.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. Selection among platforms is made by the operator according to vessel size, lesion characteristics, and deliverability requirements. Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy. INVAMED's coronary portfolio includes guiding catheters, extension catheters, and microcatheters intended to support crossing and delivery in demanding anatomy. Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting. According to INVAMED, clinical data for the ATLAS DES show target lesion revascularization rates below 5% at 12 months, a figure that reflects studied performance rather than an individual guarantee. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Coronary Artery Disease & Cardiac Interventions: A Complete Technical Guide
- How long do you take blood thinners after a stent?
- Understanding PTCA and Drug-Eluting Balloon Catheters
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.